

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR”
APPROVED BY THE FDA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that TQB3205 “Pan-KRAS inhibitor”, an innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (“**CTTQ**”, a subsidiary of the Group), has received the approval for investigational new drug (IND) application from the United States Food and Drug Administration (FDA) for the treatment of advanced malignant tumors.

TQB3205 capsule is an oral Pan-KRAS inhibitor, which can bind to multiple KRAS-mutant proteins with high affinity, while locking the KRAS protein in an inactivated state, thereby blocking downstream signaling pathways (such as the MAPK and PI3K-AKT pathways). Finally, the process effectively inhibits the proliferation of various KRAS-mutant tumor cells and delivers precise anti-tumor effects at the target level.

KRAS mutations are among the most common driver gene mutations in human cancers. Approximately 30% of all cancer cases worldwide are associated with KRAS gene mutations. Such mutations are prevalent in various high-incidence cancers, including pancreatic cancer (approximately 90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%)^[1,2]. Currently, all KRAS inhibitors approved for marketing worldwide only target the G12C mutation subtype, whereas the KRAS mutation shows a complex spectrum, covering various subtypes including G12D, G12V and G13D, which indicate significant unmet clinical needs, thus necessitating Pan-KRAS inhibitors which can broadly inhibit a range of KRAS mutation subtypes.

The Group has achieved its strategic layout in the field of KRAS: in 2024, Garsorasib (trade name: Anfangning (安方寧®), a co-developed KRAS G12C inhibitor) received the approval for marketing in China; in 2026, TQB3205, an independently developed Pan-KRAS inhibitor, received IND approvals in China and the United States, which is expected to provide treatment solutions for a wider range of patients with KRAS mutations in the future.

Sources:

- [1] Wang Y, You M, Wang Y. Alternative splicing of the K-RAS gene in mouse tissues and cell lines[J]. *Exp Lung Res*, 2001, 27(3): 255-267.
- [2] Parikh K, Banna G, Liu SV, et al. Drugging KRAS: Current perspectives and state-of-art review[J]. *J Hematol Oncol*, 2022, 15(1): 152.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 9 April 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.